Latest Retinal implant Stories
Top Retinal Surgeons Discuss Results and Learnings from Second Human Clinical Trial SEATTLE, May 13, 2013 /PRNewswire/ -- Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), today announced that the principal investigators met last week to discuss the results of the Company's second human clinical trial. Representatives from each clinical study site were in attendance, and the discussion was moderated by Professor...
Images have been transformed into pixels and projected onto a headset to help the visually impaired in everyday tasks such as navigation, route-planning and object finding. Developed using a video camera and mathematical algorithm, the researchers from the University of Southern California hope the pixels can provide more information and enhance the vision of patients already fitted with retinal implants. Lead author of the paper, James Weiland, said: "Blind people with retinal implants...
REUTLINGEN, Germany, Feb. 19, 2013 /PRNewswire/ -- Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), today announced results from part of its multicentre study were published today in the peer-reviewed journal Proceedings of the Royal Society B. The research found that, during the course of a three to nine month observation period, functional vision was restored in the majority of nine German patients implanted with a...
ROME, Feb. 1, 2013 /PRNewswire/ -- Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), and Okuvision GmbH, an innovator in the field of transcorneal electrical stimulation (TES) therapy for early and intermediate stage RP patients, today announced that research on both companies' devices will be presented at the EURETINA Winter Meeting in Rome, Italy, February 1-3. Sister companies, Retina Implant and Okuvision have...
REUTLINGEN, Germany, Nov. 8, 2012 /PRNewswire/ -- Okuvision GmbH, an innovator in the field of transcorneal electrical stimulation (TES) therapy for early and intermediate stage retinitis pigmentosa (RP) patients, today announced the start of a multi-center, post-market study for the company's CE marked OkuStim® treatment. OkuStim represents an advance in the treatment of RP, providing patients with a clinical option that has been shown to delay the progress of RP-related...
REUTLINGEN, Germany, Sept. 27, 2012 /PRNewswire/ -- Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), announced that its scientific advisory board has been debriefed on the latest results in the Company's second human clinical trial. On September 23 Lead Investigator Eberhart Zrenner, M.D., professor of Ophthalmology and founding director of the Institute for Ophthalmic Research at the Centre for Ophthalmology of the...
MILAN, Italy, Sept. 5, 2012 /PRNewswire/ -- Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), today announced that results from the Company's second human clinical trial will be presented at the 12(th) EURETINA Congress, in Milan, 6-9 September. On Friday, 7 September at 16:45 CEST Professor Eberhart Zrenner, director and chairman of the Institute for Ophthalmic Research at the Centre for Ophthalmology of the...
MILAN, Sept. 5, 2012 /PRNewswire/ -- Okuvision GmbH, the leading developer of transcorneal electrical stimulation (TES) therapy for patients with early-to mid-stage retinitis pigmentosa (RP) today announced that results from the Company's human clinical trial will be shared at the 12(th) EURETINA Congress, in Milan, 6-9 September. The abstract titled "Effects of Transcorneal Electrical Stimulation in Patients with Retinitis Pigmentosa" will be presented by Dr. Tobias Roeck from the...
A new implant designed to help the blind has allowed three test patients to see the shapes of objects just days after they were fitted with the device, research published in the British scientific journal Proceedings of the Royal Society B has revealed.The implants, which were developed by engineers at German's University of Tuebingen and medical technology firm Retina Implant AG, represent "an unprecedented advance in electronic visual prostheses" and could "eventually...
BONN, Germany, April 6 /PRNewswire/ -- IMI Intelligent Medical Implants, a pioneer developer of a system designed to restore vision to people blinded by diseases such as retinitis pigmentosa or macular degeneration, has named veteran life sciences executive, Robert J. Rosenthal, Ph.D., chief executive officer. He is also a member of the IMI board of directors. Dr. Rosenthal has more than 20 years of experience fostering product innovation and building value for customers, shareholders, and...
